David Alderman: ASH25 is Live
David Alderman, President and CEO at Molekule Consulting, shared on LinkedIn:
”Silence before the field ruptures again.
First thing you see walking into ASH25.
Black letters on white. Lobby reeks of fresh carpet glue.
Four days in Orlando will break frontline logic, erase durability curves, and force every franchise team to rewrite 2026–2030 tonight.
Hematology never sleeps in December.
Everyone else does.
If you’re here, you feel it in your chest already.
If you’re not, pay attention.
What leaves these halls this week will outlive the building.
We are already live in every lineage that pays the bills.
If today’s late-breakers just detonated your 2027 budget, find us before your competitor does.
ASH25 is live.”
All from ASH25 featured in Hemostasis Today.
-
Mar 16, 2026, 19:16Maha Othman: Delighted to See Our Article Receive The Eberhard F. Mammen Most Popular Article Award 2026
-
Mar 16, 2026, 19:03Limited Evidence for Anticoagulation Despite High VTE Risk in Sickle Cell Disease – RPTH
-
Mar 16, 2026, 18:59Bartosz Hudzik: Choosing The Right Anticoagulant for Acute Venous Thromboembolism
-
Mar 16, 2026, 18:54Michael Recht Appointed Chief Medical and Scientific Advisor to NBDF’s Pathway to Cures
-
Mar 16, 2026, 18:46David McIntosh: Moving Beyond Doubts and Ensuring the Safety of Plasma Donation
-
Mar 16, 2026, 18:42Ramy Abdelnaby: Exploring Advances in Antithrombotic Therapy for Noncardioembolic Ischemic Stroke
-
Mar 16, 2026, 18:27Christina (Tina) P: Help Advance Research and Support Patients with Antiphospholipid Syndrome
-
Mar 16, 2026, 18:20Ahmed Koriesh: Stroke Prevention in the New 2026 ACC/AHA Dyslipidemia Guideline
-
Mar 16, 2026, 18:13Nameer Ascandar: Outcomes After GI Bleeding in Patients with Rheumatoid Arthritis and AF on Long-Term Oral Anticoagulation